CARA - Cara Therapeutics, Inc.
| Previous Close | 18.43 |
| Open | 18.48 |
| Bid | 17.78 x 1400 |
| Ask | 18.33 x 1100 |
| Day's Range | 17.62 - 18.79 |
| 52 Week Range | 12.19 - 24.30 |
| Volume | 1,183,159 |
| Avg. Volume | 702,295 |
| Market Cap | 717.516M |
| Beta (3Y Monthly) | 2.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.20 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Cara Therapeutics Inc Earnings Call
- InvestorPlace•3 days ago
Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use
Cannabis company Canopy Growth (NYSE:CGC) may have just secured its highest-profile celebrity endorsement yet. Perhaps only topped by the well-publicized relationship between Oprah Winfrey and Weight Watchers (NASDAQ:WW), lifestyle icon Martha Stewart just revealed she invested in an undisclosed stake in Canopy Growth stock because cannabis and cannabinol products are an "alternative to opioids."Source: Shutterstock She's probably not wrong. Insys Therapeutics (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) are just a couple of several pharmaceutical companies developing ways to use the unique properties of the plant to make effective but not addictive pain-killers.Still, some industry experts are skeptical, and even if the CBD is the basis for an alternative to opioids the world hopes it will be, Canopy Growth role in that sliver of the cannabis movement is modest, at best. Its rise to prominence has been almost entirely driven by recreational use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTake a closer look at the company though, and you'll find a handful of the (too many) different entities Canopy Growth owns are actually taking aim at the opioid epidemic. * 7 Safe Stocks to Buy for Anxious Investors Pain Relief and Canopy Growth StockThe 77-year Stewart is as in-touch with societal trends as any millennial is, recently explaining of her investment in Canopy Growth stock to Create & Cultivate's founder Jaclyn Johnson, "Well, it's the modern thing, and it's an alternative to opioids of course."It is indeed the modern thing to do. More than 60% of Americans now favor legalizing marijuana, and cannabis has promise as a strong pain reliever.The former model and TV show host went on to undermine her case, however, adding, "I have a lot of animals, and I would love to be able to relieve stress or arthritis or other kinds of problems that my horses, my dogs, my cats experience. We're working on that first, and we're working on additions to human food stuffs, and also on cosmetics."To-date, recreational marijuana has been the crux of the story surrounding Canopy Growth. Of its fiscal Q3 sales of 10,102 kilograms, up 334% year-over-year, the vast majority of it was for recreational usage.The company isn't ignoring its potential role as a supplier of cannabis for true medicinal purposes though. Pharma and Canopy Growth StockAs of the latest look, Canopy owns eight diverse brands, including the relatively new Spectrum Therapeutics, which serves as "the company's healthcare professional and patient-facing identity in medical markets in Canada and around the world." While new, the division has still been undersold.Spectrum Therapeutics is a three-branch unit. Canadian consumers are likely most familiar with Spectrum Cannabis, which supplies medical cannabis using a clever-though-not-complicated color-coding system.It's the other two divisions of Spectrum, however, that quietly look and feel more like pharma companies than a means of simply scoring a high.Canopy Health Innovations, for instance, has secured 38 provisional patents in the United States with more on the way. Overseas, it's involved in eleven different drug-development trials.Cannabinoid Compound Company, also referred to as C3, is Europe's largest cannabinoid-based pharmaceuticals company. Granted, that doesn't necessarily mean a whole lot just yet. The company's dronabinol, however, can be "prescribed by doctors in Germany for any type of chronic pain, and for any condition in palliative care."It's a credible start towards becoming the opioid alternative Martha Stewart believes is possible.Adding to that credibility is the fact that the NFL is exploring the use of cannabis as a means of treating players' pains. That follows a partnership forged between the NHL Alumni Association and Canopy Growth earlier this year, to explore cannabinoids as a means of treating post-concussion neurological diseases… an area the NFL should be exploring as well. Looking Ahead for Canopy Growth StockDon't misread the message. An investment in Canopy Growth stock is an investment in many things, but an investment in opioid alternatives is the least of them. And, it could take years for the prescription-based use of cannabis to catch up with Canopy's recreational business. If that's the impact Stewart is betting on, it could be a long and rocky wait.It's still on the radar though. And, with the opioid market expected to be worth roughly $35 billion by 2025, it's a prospect that would certainly make for a solid second-act from the company. Or, maybe a third act, if the United States legalizes marijuana at the federal level. While certainly game-changing, recreational usage can't drive double-digit and triple-digit growth forever.Besides, the bigger the recreational market gets, the more competitive it becomes, and we've already seen the prices of marijuana fall as it becomes increasingly commoditized.Prescription-based products, preferably co-developed with a major partner, could prove to be a key means for Canopy Growth to differentiate itself and establish a longer-lasting, better-defended growth engine. You've just heard very little about the potential opportunity because it's such a long-term one.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use appeared first on InvestorPlace.
- Motley Fool•9 days ago
3 Small-Cap Biotech Stocks You Can Buy Right Now
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
- Insider Monkey•17 days ago
Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ?
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
- GlobeNewswire•18 days ago
Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
Motley Fool•18 days agoCara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript
CARA earnings call for the period ending March 31, 2019.
- Zacks•19 days ago
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•19 days ago
Cara: 1Q Earnings Snapshot
The Stamford, Connecticut-based company said it had a loss of 56 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•19 days ago
Cara Therapeutics Reports First Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and.
Market Realist•19 days agoKey Cannabis Sector Updates: Analyst Ratings and Earnings
Key Cannabis Sector Updates: Price Action and Analyst Ratings(Continued from Prior Part)Cannabis updateLast week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%. The company released its fourth-quarter and full-year 2018 earnings last
- Market Realist•19 days ago
Cannabis Stocks Had a Mixed Performance Last Week
Key Cannabis Sector Updates: Price Action and Analyst RatingsCannabis stocksCannabis ETFs traded on a negative note last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 1.2%, while the ETFMG Alternate Harvest ETF (MJ) gained 0.33%. The
- Zacks•20 days ago
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
- Investopedia•20 days ago
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- GlobeNewswire•26 days ago
Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019
STAMFORD, Conn., April 30, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
- Market Realist•27 days ago
Ups and Downs in the Cannabis Space Last Week
Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the
- ETF Trends•27 days ago
Are There Cannabis Stocks in Your Portfolio? Here’s the Straight Dope
As we approach April 20, a date that’s become something like a holiday for cannabis enthusiasts, there’s little argument that legalized marijuana is spreading like, well, a weed. Uruguay was the first country in the world to legalize cannabis for recreational use, in 2013, followed by Canada, which in 2018 became the world’s first developed nation to legalize recreational cannabis, having approved it for medicinal use back in 2001. In the United States, while it’s not legal at the federal level, as of the end of 2018 only four states have deemed cannabis to be illegal, with the majority of states approving it (as well as cannabidiol or “CBD,” the nonpsychoactive component of cannabis) for medicinal use.
- Market Realist•last month
Cannabis Updates: New Listings, Price Action, and Ratings
Cannabis Updates: New Listings, Price Action, and RatingsCannabis updateThe cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.
- ACCESSWIRE•last month
CBD Company to Research Now
HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...
- Motley Fool•last month
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
Both of these biotech stocks have tremendous momentum. Which is more likely to deliver bigger returns in the future?
- ACCESSWIRE•last month
Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering
NEW YORK, NY / ACCESSWIRE / April 11, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors. Traders News Source has created a comprehensive report on the current state of the cannabis market, including an outlook on where the industry may be headed in 2019. This report is a must read for investors in cannabis stocks.
- Motley Fool•2 months ago
Why Cara Therapeutics Stock Jumped 15.1% in March
This small biotech expects to announce results from two clinical studies in 2019.
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
- Motley Fool•2 months ago
3 Top Small-Cap Biotech Stocks for Aggressive Investors
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT
Q4 2018 Cara Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
STAMFORD, Conn., April 02, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
